FSSAI ISSUES NOTICES TO EIGHT FOOD COMPANIES OVER ALLEGEDLY MISLEADING ‘HEALTHY’ CLAIMS ON PRODUCT PACKAGING AND LABELS.
Musk’s reusable rocket company is looking to raise $75 billion, selling 555.6 million shares for $135 apiece, according to a filing with the Securities and Exchange Commission. The deal values SpaceX at $1.77 trillion, making it the seventh most-valuable U.S. company, ahead of Tesla
INDIA ISSUES 44,000+ TAX NOTICES, DETECTS ₹888.82 CRORE IN UNDISCLOSED CRYPTO INCOME IN MAJOR COMPLIANCE CRACKDOWN.
Read More:
GADKARI APPROVES LEGAL USE OF 100% ETHANOL, CALLS IT A MAJOR ALTERNATIVE TO PETROL
INDIA CLEARS 100% ETHANOL FUEL AS AUTOMAKERS PREPARE TO LAUNCH COMPATIBLE VEHICLES
TOYOTA, SUZUKI, HYUNDAI AND MG TO ROLL OUT 100% ETHANOL-COMPATIBLE CARS AFTER POLICY APPROVAL
IOL Chemicals & Pharmaceuticals: Diversification Story Emerging
Business Mix
– Pharma contributes ~60%
– Chemicals contribute ~40%
– Historically Ibuprofen-focused
– Diversifying API portfolio
Key Positive: Beyond Ibuprofen
– Scaling multiple APIs
– Paracetamol gaining traction
– Metformin growing steadily
– Clopidogrel expanding
– Pantoprazole performing well
FY26 Performance
– Revenue ₹2,319 Cr
– Revenue up 11.5%
– EBITDA up 29%
– PAT up 36%
– Margins expanded meaningfully
Q4 Momentum
– Highest-ever quarterly revenue
– Revenue up 17%
– EBITDA up 40%
– PAT up 68%
– Strong operating leverage
Non-Ibuprofen Opportunity
– Most APIs at high utilization
– Paracetamol capacity tripled
– Utilization currently 55%
– FY27 target 70-75%
– Full utilization targeted FY28
Chemicals Segment
– Ethyl acetate strong
– Acetic anhydride healthy
– Triacetin performing well
– Utilization near 100%
– Spreads improving further
Capacity Utilization
– Most products above 90%
– Demand remains strong
– Existing assets largely utilized
– Growth increasingly capex-led
Expansion Plans
– 100-acre land acquired
– Planned capex ₹1,200-1,400 Cr
– Spread over 4-5 years
– Mostly internally funded
– Significant growth runway
Regulatory Strength
– USFDA approved facilities
– EU GMP approvals
– CEP certifications
– Brazil approvals
– Strong export readiness
Export Opportunity
– Export mix still low
– Regulated markets targeted
– Better realizations possible
– Margin expansion opportunity
Key Risks
– Ibuprofen still dominant
– Commodity API exposure
– Pricing cyclicality risk
– Large capex execution risk
– Chinese competition
Management Signals
– High confidence levels
– Internal accrual funding
– Focus on efficiency gains
– Product-mix improvement
– Strong utilization trends
What To Track
– Non-Ibuprofen contribution
– Paracetamol utilization growth
– EBITDA margin above 13%
– Chemical spread sustainability
– Export market expansion
– Capex execution quality
Key Takeaway
– IOL is transitioning from an Ibuprofen-centric company into a broader API and chemicals platform. The core investment thesis is not Ibuprofen growth, but successful diversification, high asset utilization, export expansion and disciplined execution of a large multi-year capex program. The next phase of value creation will depend on how effectively the company converts this diversification into sustainable margins and higher-quality earnings.
Read More article like this on sharepricenews.com
